TScan Therapeutics, Inc. (TCRX)
| Market Cap | 60.10M -31.5% |
| Revenue (ttm) | 9.14M +106.7% |
| Net Income | -124.31M |
| EPS | -0.96 |
| Shares Out | 60.10M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 840,890 |
| Open | 1.080 |
| Previous Close | 1.110 |
| Day's Range | 1.000 - 1.100 |
| 52-Week Range | 0.882 - 2.570 |
| Beta | 1.06 |
| Analysts | Buy |
| Price Target | 6.00 (+500.0%) |
| Earnings Date | May 6, 2026 |
About TCRX
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It ... [Read more]
Financial Performance
In 2025, TScan Therapeutics's revenue was $10.33 million, an increase of 266.65% compared to the previous year's $2.82 million. Losses were -$129.77 million, 1.78% more than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for TCRX stock is "Buy." The 12-month stock price target is $6.0, which is an increase of 500.00% from the latest price.
News
TScan Therapeutics reports Q1 EPS (22c), consensus (17c)
Reports Q1 revenue $982,000, consensus $2.5M. “2026 will be a critical year for TScan as we advance our mission to deliver transformative T cell therapies to patients. We have multiple…
TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Early data on patients treated in Cohort C of the ALLOHA™ Phase 1 heme trial expected in the second quarter of 2026 Initiation of Phase 3 study of TSC-101 (ALLOHA-2 ™) planned for the second quarter ...
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting
WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell...
TScan Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference
The conference highlighted a differentiated TCR T cell therapy platform targeting post-transplant AML/MDS relapse, with phase I data showing >50% relapse reduction and long-lived responses. A pivotal trial launches mid-2024, with commercial launch expected in 2029 and strong profit margins projected. Additional HLA-targeted products and an in vivo solid tumor platform are in development.
TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
WALTHAM, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell...
TScan Therapeutics price target raised to $5 from $4 at Wedbush
Wedbush raised the firm’s price target on TScan Therapeutics (TCRX) to $5 from $4 and keeps an Outperform rating on the shares. The firm says the company reported earnings and…
TScan Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Lead TCR T-cell therapy for heme malignancies shows strong phase I efficacy and safety, with pivotal trial launching in Q2 and commercial-ready manufacturing in place. Market expansion through additional HLA-targeted products could double the addressable patient population.
TScan Therapeutics reports Q4 EPS (18c), consensus (28c)
Reports Q4 revenue $2.6M, consensus $2.42M “The regulatory and operational progress we have made over the last several months related to our heme program is exciting. We expect the momentum…
TScan Therapeutics sees cash runway into 2H27
Cash and cash equivalents as of December 31, 2025 were $152.4 million, excluding $5.0 million of restricted cash. The Company believes that its existing cash resources will be sufficient to…
TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Presented positive updated data from the ALLOHA ™ Phase 1 heme trial at 67 th American Society of Hematology (ASH) Annual Meeting and Exposition Announced completion of enrollment in Cohort C of Phase...
TScan Therapeutics completes enrollment into Cohort C of ALLOHA study
TScan Therapeutics (TCRX) announced completion of enrollment into Cohort C of the ALLOHA study. Patients in Cohort C are being treated using the new commercial-ready manufacturing process. The Company...
TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03
Completed enrollment of Cohort C in the Phase 1 ALLOHA™ trial; patients to be treated with commercial-ready manufacturing process
TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell ...
TScan Therapeutics Transcript: KOL Event
Updated data show TSC-101 delivers strong efficacy and safety in high-risk AML/MDS post-transplant patients, with a new commercial-ready process improving scalability and cost. The pivotal trial is set for Q2 next year, with plans to expand the addressable market through additional HLA-targeted products.
TScan Therapeutics announces updated data from ALLOHA Phase 1 trial
TScan Therapeutics (TCRX) announced updated results from the ongoing ALLOHA Phase 1 trial of TSC-101 in patients with heme malignancies undergoing allogeneic hematopoietic cell transplantation, HCT. T...
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities
WALTHAM, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell ...
TScan Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Maxwell Skor downgraded TScan Therapeutics (TCRX) to Equal Weight from Overweight. The firm’s new base case price target is now $1-$5 vs. $7-$13 prior. After the company’s…
TScan Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Lead heme malignancy program shows 82% relapse-free rate and is moving to a pivotal trial in Q2 next year. Solid tumor efforts pivot to in vivo engineering, and autoimmunity research advances with new target discoveries. Cash runway now extends into the second half of 2027.
TScan Therapeutics reports Q3 EPS (28c), consensus (33c)
Reports Q3 revenue $2.511M, consensus $1.98M. “Following a productive meeting with the FDA, we now have a clearly defined pivotal trial design for TSC-101, and we also have an improved…
TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Reached agreement with FDA on pivotal study design for TSC-101 following productive end of Phase 1 meeting Data from ALLOHA ™ Phase 1 heme trial to be presented at the 67 th American Society of Hemato...
TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell ...
TScan Therapeutics downgraded to Neutral from Buy at BTIG
BTIG analyst Justin Zelin downgraded TScan Therapeutics (TCRX) to Neutral from Buy without a price target following the company’s decision to prioritize its hematologic malignancy program and pause on...
TScan Therapeutics downgraded to Neutral from Buy at BTIG
BTIG downgraded TScan Therapeutics (TCRX) to Neutral from Buy.
TScan Therapeutics price target lowered to $6 from $9 at Needham
Needham lowered the firm’s price target on TScan Therapeutics (TCRX) to $6 from $9 and keeps a Buy rating on the shares. TScan is consolidating its efforts on lead heme…
TScan Therapeutics Transcript: FDA Announcement
FDA agreed to additional high-dose patient data collection before pivotal trial launch in Q2 2026. A new manufacturing process improves efficiency and is expected to enhance efficacy. Strategic focus shifts to the HEME program, with solid tumor efforts moving to in vivo engineering.